To compare and evaluate the safety and pharmacokinetic characteristics after administration of DWP16001 Drug A and DWP16001 Drug B in healthy adult volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
38
1 tablet, Oral, once daily single dose
3 tablet, Oral, once daily single dose
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea
AUC0_t of DWP16001
Area under the plasma concentration versus time curve
Time frame: 0-72 hours
Cmax of DWP16001
Peak Plasma Concetration
Time frame: 0-72 hours
Tmax Tmax
Time at Cmax Tmax
Time frame: 0-72 hours
AUC of DWP16001
Area under the plasma concentration versus time curve
Time frame: 0-72 hours
T 1/2 of DWP16001
half life of DWP16001
Time frame: 0-72 hours
CL/F of DWP16001
Apparent total clearance of the drug from plasma after oral administration
Time frame: 0-72 hours
Vd/F of DWP16001
Volume of distribution
Time frame: 0-72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.